Half-life: 46.3 hours
Main emission lines: 41.5keV, 69keV, 103keV, 539keV
Samarium-153 is a radiopharmaceutical (RFP) intended for treating patients with bone metastases accompanied by pain syndrome.
Due to its high activity, dosimetric devices often react to people with radiopharmaceuticals in their blood. Users of dosimeters frequently encounter such individuals, and it is not uncommon.